Evolution of the Thorough QT/QTc study

Regulatory Rapporteur

Volumn 7, Issue 11, 2010, Pages 20-22

  Wheeler, William ^a  

^a CELERION   (United States)

Author keywords

ICH E14; Interdisciplinary review team (IRT).; QT interval; QT prolongation; Thorough QT QTc study (TQT); Torsade de Pointes (TdP); US FDA

Indexed keywords

CISAPRIDE; MOXIFLOXACIN; PLACEBO;

DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDICATION; DRUG LEGISLATION; DRUG SURVEILLANCE PROGRAM; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; ENCAPSULATION; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART RATE; HEARTBURN; HUMAN; MEDICOLEGAL ASPECT; PEPTIC ULCER; QT INTERVAL; QT PROLONGATION; SHORT SURVEY; STOMACH PARESIS; SUDDEN DEATH; TORSADE DES POINTES;

EID: 78049394848     PISSN: 17428955     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Short Survey

References (26)

1. Committee for Proprietary Medicinal Products. 'Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products', The European Agency for the Evaluation of Medicinal Products, December 1997.
2. Haverkamp W, Breithhardt G, Camm AJ et al. 'Policy Conference - The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications', EHJ, 2000, 21(15), 1216-1231.
3. Fenichel R, Malik M, Antzelevitch C et al. 'Drug-Induced Torsade de Pointes and Implications for Drug Development', J Cardio Electro, 2004, 15(4);475-495.
4. Darpo B. 'Spectrum of drugs prolonging QT interval and the incidence of torsade de pointes', Eu Heart J, 2001 (3 Suppl. K) K70-K80.
5. US FDA. 'Janssen Pharmaceutica stops marketing Cisapride in the US', FDA Talk Paper, 23 March 2000.
6. Dear Doctor Letter, Janssen Pharmaceutica Research Foundation, 26 June 1998.
7. Lander A. 'The risks and benefits of cisapride in premature neonates, infants and children', Arch Dis Child, 1998 (79) 469-471.
8. Kohl M, Wuerdemann I, Clemen J et al. 'Cisapride may improve feeding tolerance of preterm infants: a randomized placebo-controlled trial', Biol Neonate, 2005, 88(4); 276-7.
9. Smalley W, Shatin D, Wysowski D et al. 'Contraindicated use of Cisapride Impact of Food and Drug Administration Regulatory Action', JAMA, 284(23) 3036-3039.
10. Woosley R. 'Drug Labeling Revisions-Guaranteed to Fail?', JAMA, 2000, 284 23; 3047-3049.
11. Health Canada: Draft Guidance 'Assessment of the QT prolongation potential of non-antiarrhythmic drugs,' 15 March 2001.
12. US FDA and Health Canada: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Preliminary Concept paper, 15 November 2002.
13. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs: Guidance to Industry, 2005.
14. S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals, 2005.
15. QT Guidance 'Reducing Number of Drugs Leaving Early Development, Firms Say', Pink Sheet, 17 October 2005.
16. E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs, 2005.
17. E14 Implementation Working Group Questions and Answers, ICH, 4 June 2008.
18. E-Scribe ECG Warehouse [cited 2010 Sep 25]. Available from: https://www.ecgwarehouse.com/index.php.
19. Sarapa N, Mortara J, Brown B, Isola L, Badilini F. 'Quantitative performance of E-Scribe warehouse in detecting quality issues with digital annotated ECG data from healthy subjects', J Clin Pharmacol, 2008, 48(5) 538-546.
20. I nterdisciplinary Review Teams for QT Studies. Manual of Policies and Procedures. CDER, FDA [accessed 2010 Sep 25]. Available from: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ ManualofPoliciesProcedures/ucm082015.pdf
21. QT IRT Reference Document Final 0.pdf: https://www.cardiac-safety.org/ library/QT%20IRT%20Reference%20Document%20Final%200.pdf/view
22. Zhang J, 'Thorough QT study design and baseline issues', presentation given at DIA Cardiovascular Safety in Drug Development: QT, Arrhythmias, Thrombosis, and Bleeding, held in Arlington, Virginia, 12-13 April 2010.
23. Natekar M, Hingorani P, Gupta P et al. 'Effect of number of Replicate Electrocardiograms Recorded at Each Time Point in a Thorough QT Study on Sample Size and Study Cost', J Clin Pharm, 2010. Epub 17 Sep 2010. Available from: http://jcp.sagepub.com/content/early/2010/09/17/0091270010376962.full.pdf+html
24. Norman Stockbridge, FDA, personal communication 2008.
25. Badilini F, Vaglio M, Sarapa, N. 'Automated extraction of ECG strips from continuous 12-lead holter recordings for QT analyses at prescheduled versus optimized time points', Ann Noninvasive Electrocardiol 2009, 14(Suppl1):S22-29
26. Wheeler, W. Manuscript in preparation.